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Abstract Peritoneal membrane permeability deteriorates in
peritoneal dialysis (PD) patients. We test whether glucose
degradation products (GDPs) in PD fluids, glyoxal, methyl-
glyoxal and 3-deoxyglucosone, stimulate the production of
vascular endothelial growth factor (VEGF), a factor known to
enhance vascular permeability and angiogenesis. VEGF in-
creased in cultured rat mesothelial and human endothelial cells
exposed to methylglyoxal, but not to glyoxal or 3-deoxygluco-
sone. VEGF also increased in peritoneal tissue of rats given
intraperitoneally methylglyoxal. VEGF and carboxymethylly-
sine (CML) (formed from GDPs) co-localized immunohisto-
chemically in mesothelial layer and vascular walls of the
peritoneal membrane of patients given chronic PD. By contrast,
in the peritoneum of non-uremic subjects, VEGF was identified
only in vascular walls, in the absence of CML. VEGF production
induced by GDPs may play a role in the progressive deterioration
of the peritoneal membrane.
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1. Introduction
The quality of the peritoneal membrane deteriorates pro-
gressively with peritoneal dialysis (PD) duration [1]. From a
morphological point of view, membrane alteration is charac-
terized by interstitial ¢brosis, disappearance of mesothelial
cells, vascular wall thickening, vasodilation and increased an-
giogenesis [1,2]. From a functional point of view, ultra¢ltra-
tion decreases with an eventual impairment of macromolecu-
lar di¡usion in a few patients [3].
The glucose content of the dialysate has been incriminated
in the alteration of the peritoneal membrane. Heat steriliza-
tion of PD £uids degrades glucose into a variety of carbonyl
compounds such as methylglyoxal, glyoxal and 3-deoxygluco-
sone [4,5], all of which are cytotoxic and mitogenic [6,7].
These products also lead to advanced glycation of proteins
[8,9], associated with age-related disorders and with diabetic
or uremic complications [10^13]. The e¡ect of advanced gly-
cation end products (AGEs) on the peritoneal membrane re-
mains to be elucidated.
Decreased ultra¢ltration has been taken as evidence for an
augmentation of the peritoneal surface area available for dif-
fusive exchange [1]. An increased vascular surface area within
the peritoneal membrane might thus account for the loss of
ultra¢ltration. Within this framework, the vascular endothe-
lial growth factor (VEGF) might play a critical role. VEGF
increases vascular permeability [14,15], stimulates nitric oxide
synthase production and thus vasodilation [16], and initiates
in£ammatory responses [17,18]. Finally, it is a powerful an-
giogenic factor contributing to the development of vascular
lesions [19^21].
The present paper assesses the possible role of VEGF in the
modi¢cation of peritoneal membrane characteristics. More
speci¢cally, we examine the e¡ect of methylglyoxal, a major
glucose degradation product (GDP) [4,5], on the production
of VEGF, both in vitro in cultured peritoneal mesothelial and
endothelial cells and in vivo in peritoneal tissues of rats. We
also examine by immunohistochemistry the distributions of
VEGF and GDP-modi¢ed proteins in peritoneal tissues ob-
tained from long-term PD patients. We report for the ¢rst
time that methylglyoxal enhances the production of VEGF
in peritoneal cells and propose the hypothesis that GDPs con-
tained in PD £uids impair the permeability of the peritoneal
membrane, at least in part, through an augmented production
of VEGF and its attendant stimulation of angiogenesis.
2. Materials and methods
2.1. In vitro mesothelial and endothelial cell culture experiments
Peritoneal tissue was obtained from 6 week old male CD (SD) IGS
rats (Charles-River, Kanagawa, Japan). Mesothelial cells were iso-
lated according to the method of Hjelle et al. [22] and cultured in
Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal bovine se-
rum. Human microvascular endothelial cells were purchased from
Kurabo (Osaka, Japan) and cultured in VEGF-depleted EGM-2 me-
dium (Takara, Tokyo, Japan). The mesothelial and endothelial cells at
passage 7^10 were cultured for 3 h in a CO2 incubator in the presence
of several concentrations of various GDPs, i.e. glyoxal, methylglyoxal
(Sigma, St. Louis, MO, USA) or 3-deoxyglucosone (kindly provided
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from Fuji Memorial Research Institute, Otsuka Pharmaceutical, Kyo-
to, Japan). Cellular VEGF mRNA expression was then evaluated as
described below. Mesothelial cells were also cultured for 24 h in the
presence of methylglyoxal and VEGF protein production was meas-
ured in the supernatant. The cell viability was tested by trypan blue
exclusion.
2.2. In vivo animal experiments
Six week old male CD (SD) IGS rats were given a daily intraper-
itoneal injection of 50 ml/kg of a saline solution containing various
concentrations of methylglyoxal for 10 days. Peritoneal membrane
was obtained from the parietal walls and investigated for VEGF
mRNA expression. All studies were conducted in accord with the
NIH Guide for the Care and Use of Laboratory Animals. Protocols
were approved by the Institutional Animal Care and Use Subcommit-
tee.
2.3. Detection of VEGF expression
The expression of VEGF mRNA was analyzed by semiquantitative
reverse transcriptase-polymerase chain reaction (RT-PCR). Total
RNA was isolated from mesothelial and endothelial cells using
Rneasy Mini kit (Qiagen, Germany) and from peritoneal tissue by
using ISOGEN (Nippon Gene, Tokyo, Japan). Five Wg of the RNA
was reverse-transcribed using oligo(dT)12ÿ18 primers (Gibco BRL,
Gaithersburg, MD, USA) with 200 U of RNase H-free RT (Super-
script II, Gibco BRL) and PCR ampli¢cation was performed as de-
scribed previously [11]. The oligonucleotide primer sequences are as
follows. Primers for rat VEGF were 5P-ACTGGACCCTGGCTT-
TACTGC-3P and 5P-TTGGTGAGGTTTGATCCGCATG-3P : the
full-length ampli¢ed fragment is 310 bp long. Primers for human
VEGF were 5P-GGCAGAATCATCACGAAGTGGTG-3P and 5P-
CTGTAGGAAGCTCATCTCTCC-3P : the full-length ampli¢ed frag-
ment is 271 bp long. The primers for rat and human glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) were 5P-CCTGCACCACCAA-
CTGCTTAGCCC-3P and 5P-GATGTCATCATATTTGGCAGGTT-
3P and ampli¢ed a 322 bp fragment. The G3PDH served as an internal
RNA control to allow comparison of RNA levels among di¡erent
specimens. Specimens were ampli¢ed in a DNA Thermal cycler (Per-
kin-Elmer Cetus, Norwork, CT, USA) for suitable cycles consisting of
0.5 min at 94‡C, 1 min at 60‡C and 1.5 min at 72‡C. In preliminary
experiments, reverse transcription and PCR ampli¢cation were per-
formed on various amounts of RNA for 16, 18, 21, 25, 28, 31 and 34
cycles. These experiments showed that with 28 or 30 cycles of ampli-
¢cation for VEGF mRNA and with 16 or 21 cycles of G3PDH
mRNA ampli¢cation, the di¡erences in PCR product signal were
quantitatively related to input RNA. PCR products resolved by elec-
trophoresis in 1.5% agarose and stained by ethidium bromide were
quanti¢ed by measuring the signal intensity with a quantitation pro-
gram (NIH image). Experiments were performed for each GDP con-
centration. Messenger RNA was determined in triplicate and the re-
sults were averaged for each experiment. A total of 3^4 independent
experiments were performed for each experimental condition. The
results were averaged and expressed as mean þ S.D.
In some experiments, the VEGF protein was quanti¢ed in duplicate
in the culture supernatant by enzyme-linked immunosorbent assay
(ELISA) using a kit (Quantikine: RpD Systems, Minneapolis, MN,
USA) according to the manufacturer’s technical guidelines. The ex-
periment was repeated three times.
2.4. Immunohistochemistry
Peritoneal tissues were obtained, with informed consent, from nine
non-diabetic PD patients (Table 1) during catheter reinsertion. Rein-
sertion was necessitated by catheter failure due to damage, incorrect
position and/or obstruction. The patients had never su¡ered from
peritonitis. Normal peritoneal tissue was obtained, during abdominal
surgery, from two male subjects (48 and 58 years old) with normal
renal function. The study was approved by the Human Research
Committee of Tokai University School of Medicine.
Two Wm thick peritoneal tissue sections were mounted on slides
coated with 3-aminopropyltriethoxy silane (Sigma, St. Louis, MO,
USA), depara⁄ned, rehydrated in distilled water and incubated
with pronase (0.5 mg/ml: Dako, Glostrup, Denmark) for 15 min at
room temperature in a bu¡er solution containing 0.05 M Tris^HCl
(pH 7.2), 0.1 M NaCl. The slides were washed with PBS containing
0.5% Tween 20, blocked in 4% skim milk for 2 h and subsequently
incubated with anti-VEGF rabbit IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or anti-AGE mouse IgG [23], the epitope
structure of which was identi¢ed as carboxymethyllysine (CML)
[24], overnight in humid chambers at 4‡C. The sections were washed
and incubated with 1:100 diluted goat anti-rabbit IgG conjugated
with peroxidase or goat anti-mouse IgG conjugated with peroxidase
(Dako, Glostrup, Denmark) for 2 h at room temperature, followed by
the detection with 3,3P-diaminobenzidine solution containing 0.003%
H2O2. Periodic acid-Schi¡ staining was also performed for histolog-
ical study. Immunostaining was independently evaluated for intensity
and distribution by two observers.
2.5. Statistical analyses
Data are expressed by mean þ S.D. Analysis of variance (ANOVA)
was utilized to evaluate the statistical signi¢cance of various di¡er-
ences. If a signi¢cant di¡erence was indicated by the analysis, Schef-
fe’s t-test was used to compare results obtained with di¡erent concen-
trations of methylglyoxal.
3. Results
3.1. VEGF expression in mesothelial and endothelial cells
cultured in the presence of GDPs
VEGF mRNA expression was assessed in mesothelial cells
cultured in the presence of glyoxal, methylglyoxal or 3-de-
oxyglucosone. Despite concentrations varying from 0 to 400
WM, neither glyoxal nor 3-deoxyglucosone modi¢ed VEGF
expression (data not shown). Only methylglyoxal stimulated
VEGF mRNA expression at a concentration of 400 WM
(P6 0.0005) (Fig. 1A). The sample RNAs that had not been
reverse-transcribed did not yield the PCR product (lane 13 in
Fig. 1). All cells remained viable. Mesothelial cells were also
cultured in the presence of higher concentrations of 3-deoxy-
Table 1
Immunohistochemical detection of CML and VEGF in peritoneal tissues of PD patients
Samples Gender Age (years) PD duration (months) CML VEGF
Mesothelial layer Vascular walls Mesothelial layer Vascular walls
normal1 M 48 ^ 3 þ 3 +
normal2 M 58 ^ 3 þ 3 +
PD1 F 53 3 + + + +
PD2 M 44 4 + + + +
PD3 M 43 45 + + + +
PD4 F 54 60 ++ ++ ++ +
PD5 M 52 70 ++ ++ + +
PD6 M 51 90 ++ ++ ++ ++
PD7 M 45 105 ++ ++ ++ ++
PD8 M 62 108 ++ ++ ++ ++
PD9 M 66 110 ++ ++ ++ ++
3 : negative, þ : faint, +: positive, ++: strongly positive.
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glucosone (0.625, 2.5 and 5 mM). Cells incubated with these
high levels of 3-deoxyglucosone had a decreased viability (cell
viability was 80, 55, 8% for 0.625, 2.5, 5 mM 3-deoxygluco-
sone, respectively). VEGF mRNA expression could therefore
not be measured. As a consequence of these observations,
only methylglyoxal was used in the subsequent experiments.
The release of VEGF protein in the supernatant was meas-
ured by ELISA after a 24 h culture of mesothelial cells in the
presence of various concentrations of methylglyoxal. Addition
of methylglyoxal to the medium resulted in a dose-dependent
increase of VEGF (VEGF production was 22.57 þ 1.15,
29.24 þ 2.05, 37.85 þ 8.06 pg/ml for 0, 200, 400 WM, respec-
tively). No VEGF release was detected during incubation
without mesothelial cells (data not shown).
VEGF mRNA expression was then assessed in endothelial
cells cultured in the presence of various concentrations (0^400
WM) of methylglyoxal. VEGF mRNA expression rose in a
dose-dependent manner, as shown in Fig. 1B.
3.2. VEGF expression in peritoneal tissues of rats given
intraperitoneal injection of methylglyoxal
The biological e¡ects of methylglyoxal on VEGF mRNA
expression in the peritoneum were further assessed in vivo in
rats given various amounts of methylglyoxal for 10 days into
the peritoneal cavity. As shown in Fig. 1C, VEGF mRNA
expression in samples of the parietal peritoneum increased
signi¢cantly (P6 0.05) as a function of methylglyoxal concen-
tration. On optic microscopy, the peritoneal tissue was unaf-
fected: the number of vessels, the vascular wall, the intersti-
tium and mesothelial cells remained normal.
3.3. VEGF and CML immunostaining of peritoneal tissue of
long-term PD patients
The distribution of VEGF and CML was examined by im-
munohistochemistry in the peritoneal tissues of nine patients
undergoing PD. CML is derived from GDPs such as glyoxal
and 3-deoxyglucosone [9]. An anti-CML antibody was there-
fore used as a marker of GDP-modi¢ed proteins. Results are
summarized in Table 1. Fig. 2A,D shows pictures of the peri-
toneal tissue of a representative long-term PD patient (PD6 in
Table 1). It is characterized by interstitial ¢brosis and thick-
ening and hyalinosis of vascular walls. Both VEGF and CML
co-localized in the mesothelial layers and in the vascular walls
(Fig. 2B^F). Of note, in mesothelial layer, the signal with
VEGF was weaker than that with CML. Results were similar
in the eight other patients. Fig. 2G illustrates a normal peri-
toneal sample (normal2 in Table 1). In contrast with PD
samples, VEGF was present only in the vascular walls (Fig.
2H) but was absent in the mesothelial layer (data not shown).
CML was absent in the mesothelial layer (data not shown)
and was very weak in the vascular walls (Fig. 2I). Observa-
tions were similar in the other control normal sample. No
immunostaining was observed when normal mouse IgG was
used (data not shown).
4. Discussion
The molecular events implicated in the dialysis-induced al-
teration of the peritoneal membrane are as yet unknown. We
demonstrate for the ¢rst time a link between methylglyoxal, a
GDP present in heat-sterilized PD £uids, and the stimulation
of VEGF production by peritoneal mesothelial and endothe-
lial cells.
Both levels of VEGF mRNA and protein production were
signi¢cantly augmented by methylglyoxal in cultured mesothe-
lial cells. No such phenomenon is observed in the presence of
similar concentration of glyoxal or 3-deoxyglucosone. When
the 3-deoxyglucosone concentration is raised to higher levels,
cell viability decreases, thus preventing assessment of VEGF
mRNA expression. The e¡ect of methylglyoxal is not re-
Fig. 1. VEGF mRNA expression in mesothelial cells, endothelial
cells and peritoneal exposed to methylglyoxal. Reverse transcription
was performed on total RNA from cultured rat mesothelial (A) and
human endothelial cells (B) incubated with various concentrations
of methylglyoxal and peritoneal tissues (C) of rats given daily intra-
peritoneal loads of methylglyoxal for 10 days. VEGF and G3PDH
cDNAs from mesothelial and endothelial cells were then ampli¢ed
by PCR for 30 and 21 cycles, respectively, and those from perito-
neal tissues were ampli¢ed by PCR for 28 and 16 cycles, respec-
tively. Data from one representative experiment performed in tripli-
cate are illustrated in the top part of A^C. Lanes 1^3, total RNAs
from the cells incubated with medium alone; lanes 4^6, 7^9 and 10^
12, total RNAs from the cells incubated with 100, 200 and 400 WM
methylglyoxal, respectively; lane 13, total RNAs from the cells incu-
bated with 400 WM methylglyoxal without reverse transcription.
Mean ratio of VEGF mRNA over G3PDH was calculated for each
experiment. The average of the three experiments is expressed in the
bottom part of A^C. *P6 0.05, **P6 0.005, ***P6 0.0001,
****P6 0.0005.
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stricted to mesothelial cells. It is also observed in cultured
endothelial cells and in vivo in the peritoneum of rats given
intraperitoneal injections of methylglyoxal.
The methylglyoxal level needed to enhance VEGF expres-
sion and release (V400 WM) is 20^200 times above that ob-
served in heat-sterilized PD £uid (2^23 WM) [4]. Appreciation
of the clinical relevance of the methylglyoxal e¡ect should
take into account that, in vivo in man, duration of exposure
of the peritoneal cells to the compound is much longer (sev-
eral years) than in our experimental setting (3 h for in vitro
cell culture and 10 days for in vivo rat study). The di¡erence
between methylglyoxal levels observed in PD £uid and that
needed in vitro to stimulate VEGF synthesis further suggests
that other compounds may have a similar e¡ect. Such com-
pounds need not to be derived from glucose degradation in
PD £uid. They might also originate from the uremic serum
and di¡use within the peritoneal £uid. We have recently dem-
onstrated that such a mechanism accounted for the accumu-
lation of pentosidine precursors in peritoneal dialysate during
dwell [25,26].
Our immunohistochemical observations in human perito-
neal tissue also support the existence of a link between
VEGF synthesis and GDPs. In the absence of a speci¢c anti-
body against methylglyoxal-modi¢ed proteins, we assumed
that the factors governing AGE protein modi¢cation were
similar for the various GDPs. We thus relied, as a substitute,
on an antibody against CML, a protein modi¢cation induced
by glyoxal and 3-deoxyglucosone. VEGF and CML indeed
co-localize both in the mesothelial layer and in the vascular
walls of peritoneal tissue obtained from PD patients. By con-
trast, in peritoneal samples of non-uremic subjects, VEGF
was detected only in the vascular walls, in the absence of
CML. Immunohistochemistry does not allow proper quanti¢-
cation of tissue VEGF. Nevertheless, the fact that VEGF ex-
tended to the mesothelial layers and co-localized with CML
only in PD patients suggests that the GDPs present in PD
£uid enhanced VEGF production in uremic patients given
PD.
Increased VEGF production in peritoneal cells might ac-
count, in part, for the functional deterioration of the perito-
Fig. 2. Immunohistochemical detection of VEGF and GDP-modi¢ed proteins in peritoneal tissues from a long-term PD patient (PD6) and a
normal subject (normal2). Peritoneal tissue sections from a 51 year old patient on PD for 90 months (A^F) and from a 58 year old non-uremic
patients (G^I) were stained with Periodic acid-Schi¡ (left panels) or immunostained for VEGF (middle panels) and CML (right panels). VEGF
and CML are both present in the mesothelial layer and in the vascular walls in the peritoneum of the long-term PD patient. By contrast, only
VEGF is visible in the vessels of the peritoneum of the control subject. Nuclei were counterstained with Meyer’s hematoxylin. Magni¢cation,
U80.
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neal membrane. Ultra¢ltration failure is its earliest and most
frequent manifestation [3,27,28]. It results from an increased
di¡usion of glucose out of the peritoneal cavity, leading to
early dissipation of the transmembrane osmotic gradient. This
abnormality has been ascribed to an augmented vascular peri-
toneal surface area, consistent with recent evidence of an in-
creased vascular density in peritoneal tissue of PD patients
[1,29]. VEGF might augment the vascular peritoneal surface
area by stimulating vascular permeability [14,15], vasodilation
[16] and angiogenesis [19^21]. Further studies will undoubt-
edly unravel the e¡ects of VEGF on the peritoneal membrane
and clarify the role of nitric oxide release [2] as well as the
consequences of the AGE transformation of peritoneal mem-
brane proteins.
Methylglyoxal, just as other GDPs, such as glyoxal and 3-
deoxyglucosone, contains two carbonyl groups able to cross-
link cell surface proteins. We recently demonstrated that, in
cultured rat sensory neurons, they thus led to the formation of
AGE protein adducts [30]. In murine thymocytes and ¢bro-
blasts, the same phenomenon activates protein kinases such as
c-Src and increases intracellular tyrosine phosphorylation of
several cellular proteins [31]. We further suggested that the
formation of carbonyl-mediated Schi¡ base with cell surface
protein is crucial for generation of the signal, because 2-iso-
propylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide
(OPB-9195), a potent Schi¡ base inhibitor [32,33], inhibited
the intracellular protein-tyrosine phosphorylation induced by
glyoxal [31].
Much e¡ort has been devoted to prevent the deterioration
of the peritoneal membrane. The present study o¡ers a ration-
ale for reducing GDPs such as methylglyoxal by a ¢lter ster-
ilization of PD £uid or by the replacement of glucose by
glucose polymers [1,34,35]. It should be emphasized ¢rst
that methylglyoxal is probably only one of the compounds
able to raise VEGF production and second, that enhanced
VEGF synthesis may be one among several mediators of the
functional deterioration of the peritoneal membrane.
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